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Doxorubicin (DOX) selection of CCRF-CEM leukaemia cell line resulted in multidrug resistance (MDR) CEM/A7R cell line, which
overexpresses MDR, 1 coded P-glycoprotein (Pgp). Here, we report for the first time that oncoprotein Cripto, a founding member of
epidermal growth factor-Cripto-FRL, 1-Criptic family is overexpressed in the CEM/A7R cells, and anti-Cripto monoclonal antibodies
(Mab) inhibited CEM/A7R cell growth both in vitro and in an established xenograft tumour in severe combined immunodeficiency
mice. Cripto Mab synergistically enhanced sensitivity of the MDR cells to Pgp substrates epirubicin (EPI), daunorubicin (DAU) and
non-Pgp substrates nucleoside analogue cytosine arabinoside (AraC). In particular, the combination of anti-Cripto Mab at less than
50% of inhibition concentrations with noncytotoxic concentrations of EPI or DAU inhibited more than 90% of CEM/A7R cell growth.
Cripto Mab slightly inhibited Pgp expression, and had little effect on Pgp function, indicating that a mechanism independent of Pgp
was involved in overcoming MDR. We demonstrated that anti-Cripto Mab-induced CEM/A7R cell apoptosis, which was associated
with an enhanced activity of the c-Jun N-terminal kinase/stress-activated protein kinase and inhibition of Akt phosphorylation,
resulting in an activation of mitochondrial apoptosis pathway as evidenced by dephosphorylation of Bad at Ser136, Bcl-2 at Ser70 and
a cleaved caspase-9.
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Despite advances made over the last 30 years, most acute leukaemia
remains difficult to cure owing to the development of multidrug
resistance (MDR) (Abd El-Ghaffar et al, 2006; Biscardi et al, 2006).
The most well-characterised MDR gene product in relapsed acute
leukaemia is P-glycoprotein (Pgp) encoded by MDR1 gene (Abd
El-Ghaffar et al, 2006). P-glycoprotein, an ATP-binding protein,
functions as an energy-dependent efflux pump resulting in a
decreased accumulation of several structurally unrelated drugs
including anthracyclines such as doxorubicin (DOX), epirubicin
(EPI) and daunorubicin (DAU) and vinca alkaloids such as
vinblastine and vincristine as well as epipodophyllotoxins leading
to MDR phenotype (Hayes and Wolf, 1990). A number of reagents
such as a calcium channel blocker verapamil (Vp), immuno-
suppressor cyclosporin A (CyA) and its nonimmunosuppressive
derivative PSC833 overcame MDR by inhibition of Pgp function
(Hu et al, 1990). However, the acquisition of Pgp-mediated MDR
during chemotherapy remains poorly understood, and MDR cannot
be fully overcome at this stage. A MDR variant CEM/A7R cell line,
developed by DOX selection of T-cell lymphoblastic leukaemia
CCRF-CEM cell line (Zalcberg et al, 1994), has been successfully
used as a model to study the molecular mechanisms underlying
regulation of drug resistance. A rapid upregulation of MDR1 gene
in CEM/A7R cell line was induced by anthracyclines and its
analogues (Hu et al, 1995, 1999b), and prevented by CyA and its
analogue PSC 833 (Hu et al, 1996). These results represent the
clinical development of Pgp-mediated drug resistance during
chemotherapy (Hu et al, 1999a). Although Pgp expression plays a
significant role in DOX-induced MDR phenotype, accumulated
evidence indicated that additional molecular events besides MDR1
were involved (Watts et al, 2001). Recently oncoprotein Cripto, the
founding member of the epidermal growth factor-Cripto-FRL1-
Criptic (EGF-CFC) family, was also demonstrated to be an
important factor in mediating drug resistance (Normanno et al,
2004). We have found that Cripto is upregulated in Pgp-positive
CEM/A7R cells. Cripto was first identified and sequenced from a
teratocarcinoma cDNA expressing library (Ciccodicola et al, 1989),
and is overexpressed in most cancers, implicating its role in
tumorigenesis and progression (Saloman et al, 2000).
Both Cripto and MDR1 have been demonstrated as new target
genes of b-catenin (Yamada et al, 2000; Morkel et al, 2003), a key
mediator of Wnt signalling pathway. Upregulation of MDR1 and
accumulation of b-catenin have been observed in chemically
induced rat and human liver adenomas and adenocarcinomas
(Yamada et al, 1999). It is more likely that chemically induced
intracellular accumulation of b-catenin leads to its nuclear
translocation and binding to T-cell factor and lymphoid enhancer
factor transcription factors, which transactivated MDR1 and
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sCripto along with other Wnt target genes (Seidensticker and
Behrens, 2000). This may explain why DOX selection of Pgp-
mediated MDR phenotype in the CEM/A7R cells leads to
simultaneous induction of Cripto expression.
Most chemotherapeutic agents induce tumour cells to undergo a
final apoptosis pathway (Fisher, 1994). The defects in the apoptotic
pathway represent an important mechanism for the development
of chemo–resistance (Minn et al, 1995). Cripto possesses an
N-terminal signal peptide, a unique EGF-like motif, a cysteine-rich
CFC domain and a short hydrophobic carboxy terminus, which is
essential for membrane anchorage by a glycosylphosphatidyl-
inositol (GPI) moiety (Saloman et al, 2000). The EGF-like region of
Cripto is involved in activation of c-Src (Bianco et al, 2003), ras/raf/
MAPK (Kannan et al, 1997) and PI3k/Akt/GSK-3b (Ebert et al,
1999) mediated cell proliferation and cell survival signalling
pathways. Constitutive activation of PI3K/Akt pathway promotes
MDR phenotype in breast cancer (Clark et al, 2002), prostate cancer
(Lee et al, 2004) and acute myeloid leukaemia (AML) (Grandage
et al, 2005). These observations suggest that Cripto-activated PI3K/
Akt pathway in CEM/A7R cells not only stimulates tumour growth
but also induces MDR phenotype through interruption of apoptosis
pathways activated by chemotherapeutics. In addition to drug
efflux, Pgp overexpression in the CEM/A7R cells also renders cells a
cross-resistance to caspase-dependent apoptosis stimulated by
cytotoxics and apoptotic stimulus such as Fas ligand (Smyth
et al, 1998; Johnstone et al, 1999). These results suggest that tumour
cells may use both Cripto and Pgp protein to escape cell death,
induced by chemotherapeutic drugs.
Cripto has been identified as a therapeutic target (Adkins et al,
2003; Xing et al, 2004), and the EGF-like region has been regarded
as a suitable immunotherapeutic intervention point (Hu and Xing,
2005). Two monoclonal antibodies (Mab) C4 and C13 have been
generated against a Cripto 17-mer peptide, corresponding to the
‘EGF-like’ motif of Cripto, and have shown effective inhibition of
PI3K/Akt pathway and activation of c-Jun N-terminal kinase/stress-
activated protein kinase (JNK/SAPK) pathways in colon cancer cells
(Xing et al, 2004). In this paper, we are aiming to examine whether
the Mab to Cripto could overcome the Pgp-mediated MDR and the
signalling transduction pathways interrupted by the Mab. Here, we
report that Mab C4 and C13 overcame MDR and inhibited tumour
growth of the MDR CEM/A7R cells by inhibition of Akt and
activation of JNK/SAPK and mitochondrial apoptotic pathway,
demonstrating a new strategy for overcoming Pgp-mediated MDR.
MATERIALS AND METHODS
Cell lines and cytotoxic drugs
CEM/A7R is a variant of the CEM/A7 cell line, derived by stepwise
selection in increasing concentrations of DOX from a drug-
sensitive CCRF-CEM parental cell line (Zalcberg et al, 1994),
originally developed from a patient with a T-cell lymphoblastic
leukaemia (Foley et al, 1965). CEM/A7R line was established by
growing the CEM/A7 cells in the absence of DOX for more than 2
years before subcloned in 96-well plates by a limited dilution
technique (Hu et al, 1995). Daunorubicin, EPI and cytosine
arabinoside (AraC) were obtained from Pharmacia & Upjohn Pty
Limited (Perth, Australia). Verapamil was purchased from Knoll
Pty Limited (NSW, Australia). Rh123 was obtained from Sigma
(Australia). The CEM/A7R and CCRF-CEM cells were cultured in
RPMI 1640 containing 10% heat-inactivated FCS at 371Ci na5 %
CO2 humidified incubator.
Cripto Mab
Production and characterisation of anti-Cripto EGF-like region
Mab C4, C13 have been recently described (Xing et al, 2004).
Briefly, a 17-mer peptide from the EGF-like region amino acids
97–113 (CPPSFYGRNCEHDVRKE) of Cripto was synthesised
using an Applied Bio-systems Model 430A automated peptide
synthesiser (Foster City, CA, USA) as immunogen. Murine
myeloma NS1 cells were fused with spleen cells from Lewis female
rats that were immunised three times. First immunization was
injected intraperitoneally by 100mg Cripto 17-mer conjugated to
keyhole limpet haemocyanin (KLH); and emulsified in complete
Freund’s adjuvant. After 4 weeks, a second injection of Cripto
17-mer-KLH with incomplete Freund’s adjuvant, and 3 days later,
a third injection was given without adjuvant. The supernatants of
hybridomas were tested by enzyme-linked immunosorbent assay
and immunohistochemistry for their activity and specificity. C4
and C13 Mab were further selected by cell growth assays, and
purified from ascites by Sephacryl S300 HR gel filtration after 50%
saturated ammonium sulphate precipitation. The subclasses of the
Mab were determined using anti-rat immunoglobulin subclass
antibodies (ICN, Irvine, CA, USA).
Cell proliferation assays
[
3H]-thymidine incorporation assay was performed as previously
described (Hu et al, 1990). Briefly, 5 10
4well
 1 of CEM/A7R or
parental CCRF-CEM cells were cultured for 48h at 371Ci n5 %C O 2
with varying concentrations of Cripto Mabs and chemotherapeutic
agents DAU, EPI or AraC. The cells were pulsed with [
3H]-
thymidine (final concentration 1mciml
 1) for 4h and then
harvested onto glass filter papers using an automated cell harvester
and radioactivity was measured by TopCount (Perkin–Elmer,
Boston, MA, USA). All assays were performed in triplicate and the
results were expressed as percentage of [
3H]-thymidine incorpora-
tion in the treated group to control (medium only) (Xing et al,
2004). Inhibition of cell growth by Mab equals the percentage of
thymidine incorporation of control minus that of treated samples.
The results obtained from the assay are comparable from cell
growth inhibition assay by using the trypan blue dye exclusion
method (Hu et al, 1990; Xing et al, 2004).
Tumour eradication induced by Mab in SCID mice
Severe combined immuno deficiency (SCID) mice (female, 10–12
weeks of age) were obtained from the Animal Resources Centre,
Western Australia, and maintained under specific-pathogen-free
conditions for the studies. All animal experiments were approved
by Animal Ethics Committee, Austin Health, Australia, and were
carried out in accordance with the standards required by the
Guidelines for the Welfare of Animals in Experimental Neoplasia
(UKCCCR guidelines). The SCID mice were inoculated subcuta-
neously with CEM/A7R cells (2 10
7). To examine antitumour
efficacy of the Cripto Mab on an established tumour in SCID mice,
treatment was not started until the tumours size had reached
an average size of 100mm
3. C13 Mab (0.5mg per mouse) was
administrated intraperitoneally on day 6, then followed by 0.25mg
C13 twice a week for 3 weeks. Tumours were measured at 2–4 days
intervals with a caliper, and tumour size was calculated
(length width height) as described previously (Xing et al,
2004).
Flow cytometry analysis
Annexin-V binding assay Antibody-induced apoptosis was ex-
amined by Annexin V and propidium iodide (PI) dual staining to
detect early apoptotic cells (Vermes et al, 1995). Cells (2 10
5)
were incubated with or without 25mgml
 1 of Cripto Mab for 4h at
371C in a humidified chamber containing 5% CO2. The Annexin
binding assay was performed using the ApoTarget
Tm Annexin-V
fluorescein isothiocyanate (FITC) Apoptosis kit (Biosource, CA,
USA). The kit is designed to detect apoptotic cells by flow
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Dickinson, Franklin Lakes, NJ, USA).
Cripto and Pgp expression Cells (5 10
5) were incubated with
10mgml
 1 of C13 or PE-conjugated UIC2 (Colter) at room
temperature for 15min. Nonspecific rat immunoglobulin (Ig)M
and murine Mab IgG2a (Chemicon, CA, USA) were used as control
for Cripto or Pgp expression, respectively. After three washes the
cells were directly analysed for Pgp expression. For Cripto
expression, the cells were further incubated with a fluorescein-
conjugated sheep anti-rat antibody (Chemicon) at 1:80 dilution.
Mean channel fluorescence (MCF) was recorded and the expres-
sion of Pgp, Cripto was shown as the ratios of the arithmetic MCF
of UIC2 or C13 relative to the control antibodies (Hu et al, 1999a).
Rh123 accumulation Rh123 is a fluorescence dye that can be
taken up by the cells and pumped out by the Pgp pump. Rh123
accumulation in cells is a sensitive and selective measure of the
transport function of Pgp, and can be detected by flow cytometry.
Briefly, 5 10
5 cells were incubated with or without 25mgml
 1
Cripto Mab C13, C4 or 10mm Vp for 3h, respectively. The cells
were washed and the fluorescence was measured after the addition
of Rh123 at 200ngml
 1 to the culture medium in the presence or
absence of Mab or 10mm Vp. The cells were then incubated in the
dark at 371C for 1.5h. Rh123 fluorescence was measured through a
530 DF 30-nm filter. The results were expressed as the ratios of MCF
in the presence or absence of Vp or Mab (referred to as Rh123 ratio)
(Hu et al, 1999a). An increase in Pgp function by Mab was defined
as a change in the Rh123 ratio of treated and untreated cells.
Western blot
Cells (5 10
6) were treated with Mab C4 for various times in the
presence or absence of AraC for 3 or 6h. The cells were harvested,
and washed with ice cold PBS, then lysed and sonicated in 0.5ml
lysis buffer containing 20mM Tris (pH 7.5), 150mM NaCl, 1mM
EDTA, 1mM EGTA, 1% Triton X-100, 2.5mM sodium pyrophos-
phate, 1mM b-glycerolphosphate, 1mM sodium orthovanadate
(Na3VO4), 1mgml
 1 leupeptin and 1mM phenylmethyl sulfonyl
fluoride. The lysed samples were separated by 12.5 or 7.5% (for Pgp
only) SDS-PAGE and transferred onto a polyvinylidene difluoride
membrane (PVDF) (Amersham Pharmacia Biotech, Piscataway,
NJ, USA). The blots were blocked with 5% no-fat dry milk in Tris-
buffered saline buffer with 0.1% Tween-20 at room temperature for
1h and probed with appropriate dilution of anti-Cripto Mab C13 or
MDR1 (G-1) (Santa, Cruz, sc-13131), or cell signalling antibodies
(New England Biolabs) including anti-phospho-Akt at Ser473
(#9271), anti-Phospho Bcl-2 at Ser 70 (#2871), anti-Bcl-XL
(#2762), anti-Bad (#9292), anti-Phospho-Bad at Ser112 (# 9191),
anti-Phospho-Bad at Ser136 (#9295) and anti-cleaved caspase 9 at
Asp330 (#9501) antibodies. The proteins in the PVDF membranes
were visualised using chemiluminescence reagent (Perkin-Elmer)
after adding horseradish peroxidase-labelled secondary antibodies.
JNK/SAPK assay
The JNK/SAPK activity was measured using JNK/SAPK assay kit
(New England Biolabs) as described previously (Xing et al, 2004).
Briefly, a recombinant fusion protein c-Jun residue 1–89 and
glutathione S-transferase (GST-c-Jun) were used as the substrate
for activated JNK. The supernatant of cell lysate was incubated
with immobilised GST-c-Jun fusion protein overnight at 41Ct o
precipitate activated JNK. Kinase reaction was carried out in vitro
at 301C for 30min in kinase reaction buffer (25mM Tris–HCl (pH
7.5), 5mM b-glycerolphosphate, 2mM dithiothreitol, 0.1mM
sodium orthovanadate and 10mM MgC12) containing 100mM
ATP. Phosphorylation of GST-c-Jun on Ser-63 was analysed by
immunoblotting using anti-phospho-specific c-Jun (Ser-63).
Statistical analyses
Two-way analysis of variance (ANOVA), GraphPad Prism Version
4.0 (GraphPad Software Inc., San Diego, CA, USA) was used to
analyse the experiment results expressed as mean7s.d. The
Mann–Whitney nonparametric U-test was used to compare the
tumour sizes in groups of mice treated with Mab and PBS,
respectively. Po0.05 was considered to be significantly different
(Slinker, 1998).
RESULTS
Cripto expression and drug resistance
To determine whether DOX selection of MDR CEM/A7R cells
upregulated not only Pgp but also Cripto, Western blot analysis
was performed using cell lysates of CEM/A7R and CCRF-CEM cells
and probed by Mab to Pgp and anti-Cripto Mab C13. As shown in
Figure 1A, MDR CEM/A7R cells overexpressed Pgp (170kDa),
whereas drug-sensitive cell line CCRF-CEM did not express Pgp.
In contrast, though both cell lines expressed Cripto, CEM/A7R
expressed higher level of Cripto than CCRF-CEM (Figure 1A). Flow
cytometric analysis using PE-conjugated Pgp Mab UIC2 showed
that ratios of MCF of UIC2 vs control IgG2a were 1.0 (8.8/8.9), 3.2
(34.5/10.7) in CCRF-CEM (Figure 1B) and CEM/A7R, (Figure 1C)
respectively, implicating a threefold increase of Pgp expression in
the CEM/A7R cells compared to parental CCRF-CEM cells. Cripto
expression measured by C13 binding in flow cytometry analysis
showed the ratios of Cripto expression were 2.7 (32.1/12.7) in
CCRF-CEM (Figure 1D) and 4.6 (80.6/17.5) in CEM/A7R
(Figure 1E) respectively, demonstrating 1.7-fold increase of Cripto
expression in the CEM/A7R compared to the CCRF-CEM cells.
The Pgp-positive CEM/A7R cells were extremely resistant to EPI
compared with the Pgp-negative CCRF-CEM cells. CEM/A7R cells
showed 900-fold increase of resistance to EPI and 18.3-fold
increase of resistance to DAU than its parental CCRF-CEM cells
when compared at IC50 levels (0.9/0.001) for EPI (Figure 1F) and
(0.22/0.012 of IC50s) for DAU (Figure 1G) in [
3H]-thymidine
incorporation assay, respectively.
Inhibition of cell proliferation by Cripto Mab
Anti-Cripto Mab C13 and C4 inhibited cell growth of both CEM/
A7R and CCRF-CEM in a dose-dependent manner by the [
3H]-
thymidine incorporation assay. However, the MDR CEM/A7R cells
were more sensitive to inhibition effects of C13 and C4 than CCRF-
CEM cells. C13 at 6.25, 12.5 and 25mgml
 1 inhibited 32.3, 74.1 and
93.2% of [
3H]-thymidine incorporation in CEM/A7R in contrast
to 0, 25.2 and 50.7% of inhibition in CCRF-CEM, respectively
(Figure 2A). The IC50 levels of C4 and C13 were 5.5 and
8.25mgml
 1 in the CEM/A7R cells and 18.8 and 25mgml
 1 in
the CCRF-CEM cells. Therefore, compared to CCRF-CEM cells,
CEM/A7R cells were three times more sensitive to antitumour
activity of Cripto Mab (Figure 2A). This could be due to the
difference in the levels of Cripto expression in the two cell lines
(Figure 1A, D and E).
Inhibition of MDR CEM/A7R tumour growth in SCID mice
The anti-MDR tumour effect of Cripto Mab was further
investigated in MDR CEM/A7R xenograft model in SCID mice
(Figure 2B). The SCID mice with established tumours (average
size 101717mm
3) were treated with C13 (0.5mg per mouse) on
day 6, followed by six injections of 0.25mg (total of 2.0mg
per mouse) as indicated in Figure 2B. The tumour size was reduced
significantly in the C13-treated group (300mm
3) compared with
untreated control (1480mm
3, n¼6; Po0.05), and 80% of reduced
tumour size at day 26, 6 days after last C13 treatment, indicating
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sthe inhibitory effects of anti-Cripto Mab were durable, and
may be of value in the treatment of drug resistant leukaemia
(Figure 2B).
Apoptosis induced by Cripto Mab
The binding of Annexin-V-FITC conjugates to cells permits
differentiation of apoptotic cells from nonapoptotic cells. Flow
cytometry analysis demonstrated 5.9, 44.9 and 12.1% of Annexin
V-FITC and PI-double stained cells after 4h incubation of CEM/
A7R cells with medium (Figure 3A) only, C4 (Figure 3B) and C13
(Figure 3C). In contrast, there were 4.7% in medium (Figure 3D),
17.1% and 9.6% in C4 (Figure 3E) and C13 (Figure 3F) of Annexin
V-FITC and PI-positive CCRF-CEM cells, respectively. The results
indicated that the anti-Cripto Mab-induced higher proportions of
apoptosis in CEM/A7R (Figure 3B and C) than CCRF-CEM cells
(Figure 3E and F).
Cripto Mab sensitise MDR cells to Pgp substrate EPI
and DAU
To determine the effect of anti-Cripto Mab on enhancing
cytotoxicity of EPI or DAU, a range of concentrations of each
reagent was used on cell growth inhibition of CEM/A7R cells. Mab
C13 inhibited 14.8, 60.2 and 74.7% of [
3H]-thymidine incorpora-
tion at concentrations of 3.13, 6.25 and 12.50mgml
 1. As shown in
Figure 4A, the addition of 3.1mgml
 1 of C13 to the culture
containing noncytotoxic concentrations of 0.11, 0.33 and
1.0mgml
 1 EPI inhibited 40.4, 73.5 and 86.2% of [
3H]-thymidine
incorporation. Combined use of 3.1mgml
 1 C13 with 0.037, 0.11
and 0.33mgml
 1 DAU showed growth inhibition of 50.2, 81.7 and
91.2%, respectively, compared to 11.8, 41.5, 67.5 inhibited by DAU
alone (Figure 4B). Similar results were seen with 6.25mgml
 1 C13
in combination with EPI or DAU (Figure 4A and B). It is obvious
that combined use of the anti-Cripto Mab and cytotoxic drugs
significantly enhanced the inhibitory effect of each reagent
compared with use alone. Importantly, more than 90% of [
3H]-
thymidine incorporation inhibition can be achieved by combined
use of C13 at less than 50% of inhibition concentrations with
noncytotoxic concentrations of EPI or DAU (Figure 4A and B).
Two-way ANOVA analysis demonstrated that there were synergis-
tic effects in most combinations of C13 and EPI or DAU (Po0.05
or Po0.01, Po0.001 as indicated by *, **, *** in Figure 4A and B).
These results indicate that Cripto Mab C13 at less than IC50
concentrations could reverse drug resistance in the MDR CEM/
A7R cells. Similar results were observed in the combined use of C4
and EPI or DAU (data not shown).
Cripto Mab sensitise MDR cells to non-Pgp substrate AraC
Non-Pgp substrate AraC at noncytotoxic concentrations of 0.0015,
0.003 and 0.005mgml
 1 (pIC50) generated 1.4, 5.7 and 39.7% of
inhibition of [
3H]-thymidine incorporation respectively in CEM/
A7R cells. C4 alone inhibited 0, 18.2 and 82.9% of [
3H]-thymidine
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Figure 1 P-glycoprotein, Cripto expression and association with drug sensitivity in CEM/A7R and parental CCRF-CEM cells. (A) Western blot analysis of
Cripto and Pgp expression in the CEM/A7R and CCRF-CEM cells using anti-Cripto Mab C13 and Mab to 1040–1280 amino acid of human Pgp. (B and C)
P-glycoprotein expression measured by flow cytometric analysis using PE-conjugated UIC2 (solid histogram) compared to an IgG2a (open histogram) and
Pgp levels were expressed as the ratio of MCF of UIC2 vs a IgG2a control in CCRF-CEM and CEM/A7R. (D and E) Cripto expression was measured by flow
cytometry using C13 (solid histogram) compared to an IgM control (open histogram) in CCRF-CEM and CEM/A7R. Cripto levels were expressed as the
ratio (R) of the MCF of C13 vs the IgM control. (F and G) Percentage of control in [
3H]thymidine incorporation of CEM/A7R and CCRF-CEM in the
presence of increasing concentrations of EPI and DAU for 48h. Points are means of triplicate experiments. Error bars represent the s.d. in triplicate
experiments.
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sincorporation of CEM/A7R at concentrations of 1.0, 2.5 and
10.0mgml
 1, respectively. The addition of 2.5mgml
 1 C4 to the
tissue culture medium containing 0.0015, 0.003 and 0.005mgml
 1
of AraC generated 37.1, 44.7 and 76.9% of inhibition of [
3H]-
thymidine incorporation, respectively, in the CEM/A7R cells. A
95.2% of inhibition was obtained by combined use of 10.0mgml
 1
C4 and 0.005mgml
 1 AraC (Figure 4C). The results indicated that
combined use of the anti-Cripto Mab and AraC significantly
enhanced the inhibitory effect than when they were used alone.
Two-way ANOVA analysis demonstrated the combined use of
C4 and AraC had a synergistic effects (Po0.05 or Po0.01, as
indicated by *, or ** in Figure 4C). A synergistic effect was also
observed in combination of C13 or C4 and AraC in CCRF-CEM
cells (data not shown).
Rh123 accumulation by Cripto Mab
The effects of C13 on Pgp function were determined by
comparison with Pgp modulator Vp on intracellular accumulation
of Rh123 fluorescence, a sensitive assay for assessment of Pgp
function and the results were expressed as ratios of MCF of Rh123
(Hu et al, 1999a). P-glycoprotein modulator Vp at 10mM increased
Rh123 accumulation in CEM/A7R cells by 2.9-fold (751/259)
(Figure 5C) and had no significant effect on the Pgp-negative
CCRF-CEM cells (ration 0.94; 1275/1361) (Figure 5A). The data
demonstrated that overexpression of Pgp resulted in threefold
decrease (2.90/0.90) of Rh123 accumulation in CEM/A7R than
CCRF-CEM cells (Figure 1A and C). Figure 5B and 5D shows the
changes of Rh123 accumulation in the CEM/A7R cells following 3h
incubation with C13. Verapamil increased accumulation of Rh123
at similar extent (ratio 2.87:526/183) (Figure 5B) compared to the
CEM/A7R cells (ratio 2.90) (Figure 5C). In contrast, C13 alone had
little effect on intracellular Rh123 in the CEM/A7R cells after C13
treatment (ratio 0.97:181/186) (Figures 5D). Similar results were
seen in the cells treated with C4 (data not shown). The results
indicated that C13 and C4 had little effect on inhibition of Pgp
function, suggesting the effects of anti-Cripto Mab on the
overcoming drug resistance were Pgp independent.
The effect of Cripto Mab and AraC on regulation of Pgp
expression
It has been previously shown that Pgp substrates anthracyclines
and its analogues as well as non-Pgp substrate AraC differentially
upregulated Pgp expression in the CEM/A7R cells (Hu et al, 1995,
1999b) and in blast cells from AML, respectively (Hu et al, 1999a).
In the present study, the regulation of Pgp expression by C4 or
AraC and the combined use of C4 and AraC were analysed by
Western blot and flow cytometry. CEM/A7R cells were treated for
6h with 10mgml
 1 C4, 0.02mgml
 1 AraC individually or in
combination. Western blot analysis showed C4 slightly decreased
Pgp expression in CEM/A7R cells in the presence or absence of
AraC (Figure 5E). P-glycoprotein expression had no significant
changes in ratios tested by flow cytometry following the above
treatment (data not shown).
Activation of SAPK/JNK signalling pathway
Signalling events involved in the anti-MDR tumour effects of
Cripto Mab on MDR CEM/A7R cells were examined by
comparison of C4 and non-Pgp substrate AraC and their
combination on the activation of stress-activated protein kinase/
c-Jun N-terminal kinase (SAPK/JNK) proapoptotic pathways.
Stress-activated protein kinase/c-Jun N-terminal kinase is acti-
vated by multiple forms of stress including UV, radiation,
inflammatory cytokines, and has been implicated as a mediator
of stress-induced apoptosis (Davis, 2000). A sustained activation of
SAPK/JNK led to cancer cell apoptosis (Xia et al, 1995). Activation
of SAPK/JNK proapoptotic pathways was examined by using JNK
kinase assay in the cell lysates from CEM/A7R cells treated with
10mgml
 1 C4, 0.02mgml
 1 AraC for 3 and 6h or in combination
(Figure 6A). c-Jun N-terminal kinase activity was increased at 3h
of incubation of CEM/A7R cells with 10mgml
 1 C4 compared to
control, and remained at the elevated level by 6h. In contrast,
0.02mgml
 1 AraC significantly activated JNK with higher level
than C4 at 3h incubation, and declined at 6h. Combined use of C4
and AraC-enhanced JNK activity compared to C4 and AraC alone
by 6h (Figure 6A). The results indicated that C4 and AraC alone
activated JNK activity and combination treatment showed a
sustained enhancement of JNK activity by 3 and 6h (Figure 5A).
Inhibition of Akt by Cripto Mab
Tumorigenesis of Cripto is related to its activation of c-Src, MAPK
and PI3K/Akt pathways (Kannan et al, 1997; Ebert et al, 1999;
Bianco et al, 2003). Akt is activated by Cripto through
phosphorylation of Ser473 at the COOH-terminus to promote cell
survival and proliferation (Ebert et al, 1999). Moreover, JNK-
dependent apoptotic signalling pathway can be blocked by
activation of survival signalling Akt (Xia et al, 1995). An inhibition
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Figure 2 Inhibition of cell growth of CEM/A7R by anti-Cripto Mabs in
vitro and in vivo.( A) Percentage of control in [
3H]thymidine incorporation
of CEM/A7R and CCRF-CEM in the presence of C4 and C13 for 48h.
Points are means of triplicate experiments. Error bars represent s.d. in
triplicate experiments. (B)I nvivo antitumour effect of anti-Cripto Mab C13
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sof Phospho-Akt at Ser473 has been demonstrated in Western blot
analysis of CEM/A7R cells after 3h incubation with 10mgml
 1 C4
or 0.02mgml
 1 AraC, respectively (Figure 6B). The most effective
inhibition of phospho-Akt was observed by incubation of CEM/
A7R with 10mgml
 1 C4 and 0.02mgml
 1 AraC (Figure 6B). No
changes in the levels of P44/42 (MAPK) or p38 were shown after
treatment of the cells with C4 or AraC for 3h (data not shown).
The expression of Cripto was unchanged before and after
treatment (Figure 6B).
Caspase-9 cleavage
Caspase 9 is an initiator for caspase. Cleaved caspase 9 is an
activated form of caspase 9 and further processes other caspases,
including caspase 3 and caspase 7, which amplify the cascade
leading to apoptosis. c-Jun N-terminal kinase is required for the
stress-induced apoptosis mediated by mitochondrial/caspase-9
pathway (Tournier et al, 2000). Akt phosphorylates caspase-9 and
inhibits caspase-9 protease. As shown in Figure 6A and B, JNK
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the appearance of cleaved caspase-9 at Asp330 (37kDa). The most
enhanced induction of cleaved caspase-9 was induced by
combined use of C4 and AraC (Figure 6B). This may explain the
synergistic effect of anti-Cripto Mab to sensitise MDR CEM/A7R
cells to AraC.
Bad, Bcl-2 as apoptosis targets of anti-Cripto Mab
Bad is a proapoptotic member of the Bcl-2 family that is capable of
forming heterodimers with Bcl-2 or Bcl-xL, and antagonises their
antiapoptotic activity leading to cell death. Phosphorylation of Bad
at Ser 136 by Akt or at Ser 112 through Ras/Raf/MAPK cascades
resulted in the binding of Bad to 14-3-3 proteins, and inhibition
of Bad binding to Bcl-2, Bcl-xL in promotion of cell survival
(Zha et al, 1996). Thus, only dephosphorylation of Bad is
associated with apoptosis. In the CEM/A7R cells, we demonstrated
that C4 at 10mgml
 1 or AraC at 0.02mgml
 1 dramatically
decreased phosphorylation of Bad at Ser136, but not at Ser112.
C4 and AraC also significantly inhibited phosphorylation of Bcl-2
at Ser70, which was associated with cell survival in CEM/A7R.
Treatment of CEM/A7R cells with combined use of C4 and AraC
further decreased phosphorylation of Bad at Ser136, Bcl-2 at Ser70
and slightly decreased Bcl-xL. However, total Bad protein was not
affected by any treatment (Figure 6C).
DISCUSSION
Multidrug resistance related protein 1 (MDR1) related multiple-
drug resistance remains a major impediment undermining
successful cancer treatment. Despite the recent developments of
understanding the mechanisms, there is no effective method to
treat relapsed cancer, which has developed MDR after failure of
chemotherapy. Many studies focus on overcoming MDR through
modulation of Pgp function. These include Pgp modulators Vp,
CyA, PSC833, and recently developed anti-CD19 (Ghetie et al,
1999), anti-CD20 Mab (Demidem et al, 1997) and anti-Pgp Mab
(Smyth et al, 1998). In addition to inhibition of Pgp function as
drug efflux pump, these agents also showed inhibition of MDR1
expression during chemotherapy (Hu et al, 1996, 1999a) or
interrupted interactions between Pgp and targeted antigen by
antibodies leading to a dysfunction of Pgp (Ghetie et al, 2004).
However, Pgp not only functions as a drug efflux pump, but also
interrupts apoptotic pathways (Smyth et al, 1998; Johnstone et al,
1999). Here we demonstrated a distinguished strategy to overcome
MDR in CEM/A7R cells by induction of cancer cell apoptosis
signalling pathways using Mab to Cripto, a recently identified
unique target for cancer therapy (Adkins et al, 2003; Xing et al,
2004; Hu and Xing, 2005). Cripto was found to be overexpressed in
the CEM/A7R cells that acquired Pgp-mediated MDR by DOX
treatment (Zalcberg et al, 1994). Activation of c-Src and MAPK/
PI3K/Akt pathways (Bianco et al, 2003) by Cripto involves in the
cell proliferation and survival, resulting in an intervention of
chemotherapeutics-induced apoptosis pathways and promotes
MDR as demonstrated in several cancers (Grandage et al, 2005).
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Figure 5 P-glycoprotein function and expression affected by anti-Cripto
Mab in CCRF-CEM and CEM-A7R tested by flow cytometry and Western
blot. (A and C) Flow cytometry analysis of Rh123 accumulation in the
absence (open histogram) or presence of 10mM Vp (solid histogram). (B)
Rh123 accumulation in the CEM/A7R cells following 3h treatment with
25mgml
 1 C13 in the absence (open histogram) or presence of 10mM Vp
(solid histogram) or in the absence (open histogram) or presence of
25mgml
 1 C13 (solid histogram) (D). P-glycoprotein function is expressed
as the ratio of MCF in the presence or absence of Vp or C13 as described
in the ‘Materials and Methods’. P-glycoprotein levels were expressed as the
ratio (R) of the MCF. (E) Western blot analysis of Pgp expression detected
by Mab to human Pgp in the CEM/A7R cells following 6h treatment with
10mgml
 1 C4, 0.02mgml
 1 AraC and combined use of the two reagents.
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Figure 6 Western blot showing signalling molecules mediated by C4,
AraC and combination of the two reagents in the CEM/A7R cells. (A)
Activation of JNK/SAPK examined by JNK kinase assay and blotted by anti-
phosphor-c-Jun Mab in CEM/A7R cells treated with 10mgml
 1 C4 and
0.02mgml
 1 AraC or combination for 3 or 6h. (B) Western blot analysis
of phospho-Akt at Ser473 and cleavage of caspase 9 at Asp330 compared
to the level of expression of Cripto and (C) Western blot analysis of
phosphor-Bad at Ser136, Ser112, total Bad protein, phosphor-Bcl-2 at
Ser70, Bcl-xL in the same cell lysates.
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in controlling MDR mediated by Pgp and the MRP1, MRP2
(Abdul-Ghani et al, 2006). As MDR1 and Cripto are b-catenin
target genes (Yamada et al, 2000; Morkel et al, 2003), coexpression
of Pgp and Cripto in CEM/A7R cells could be simultaneously
induced by intracellular accumulation of b-catenin during DOX
selection, resulting in multiple defects in apoptosis pathways
(Watts et al, 2001). We demonstrated that Mab to a 17-mer peptide
within the EGF-like region of Cripto, C4 for example, induced
massive induction of apoptosis in the CEM/A7R cells (Figure 3),
which is three times higher than that in the Pgp-negative CCRF-
CEM cells, and correlated to the expression levels of Cripto (Figure
1A and E). As a result, these anti-Cripto Mab inhibited Pgp-
positive CEM/A7R cell growth in vitro and established tumour
growth in vivo (Figure 2).
Molecules known to predispose cells to apoptosis have shown to
enhance sensitivity of tumour cells to a variety of chemother-
apeutic agents (Fisher, 1994). We propose that anti-Cripto
Mab could overcome MDR phenotype in Pgp expressing MDR
cells by induction of apoptosis. As expected, anti-Cripto Mab
overcame MDR, and combined use of Cripto Mab C13 with
anthracyclines completely reversed resistance of MDR CEM/A7R
cells to EPI and DAU (Figure 4A and B). These observations
indicated that the residual of the drug-resistant tumour cells
could be eradicated by the addition of low concentrations of anti-
Cripto Mab to the originally unresponsive concentrations of
chemotherapeutic Pgp substrates to prevent tumour cells from
recurrence. Synergistic effect was also observed between interac-
tions of anti-Cripto Mab and non-Pgp substrate AraC (Figure 4C).
The findings may be clinically significant, because AraC has been
used for many years in the treatment of AML, and the resistance to
AraC remains a major obstacle in the effective treatment
(Fernandez-Calotti et al, 2005). We also demonstrated that the
reversal of Pgp-mediated MDR by anti-Cripto Mab in the Pgp-
positive CEM/A7R cells is irrelevant to Pgp function (Figure 5).
These results indicated that MDR could be targeted by anti-Cripto
Mab to bypass the Pgp through targeting a signal molecule to
induce apoptosis in MDR tumour cells with overexpression of
Cripto and Pgp. This strategy could be superior to targeting Pgp
function as a low level of Pgp is expressed in many normal tissue
cells such as liver, biliary tract, brain, kidney and intestines, which
play roles in the excretion of toxins. Modulation of Pgp function
caused decreased excretion of drugs and enhanced toxicities, such
as nausea and vomiting, increased myelosuppression and hyper-
bilirubinemia (Szakacs et al, 2006). No obvious side effect was
observed in the mouse model treated by anti-Cripto Mab.
However, it should be investigated in future clinical trials using
humanised Mab.
The molecular basis for anti-Cripto Mab in the induction of
apoptosis and enhancing cytotoxicity of chemotherapeutics was
examined on activation of JNK/SAPK and inhibition of Akt
pathways. We found that JNK/SAPK pathway was activated by
anti-Cripto Mab and AraC in the CEM/A7R cells. Combined use of
Mab and AraC enhanced JNK activation by 6h compared with
them used alone (Figure 6A). Stress-activated JNK/SAPK apoptosis
pathway is closely related to an alteration of dual function of Axin,
a multidomain scaffold protein, which coordinates a variety of
critical factors in determination of activation of JNK-apoptotic
pathway or Wnt oncogenic signalling pathway (Zhang et al, 2001).
In the CEM/A7R cells, PI3K/Akt pathway is intrinsically activated
by Cripto (Ebert et al, 1999). Presumably, anti-Cripto Mab inhibits
phosphorylation of Akt, a major molecule of PI3K/Akt pathway
and interrupted Cripto/Akt/GSK-3b signalling pathways leading to
destabilising b-catenin (Neo et al, 2000) and switching Axin to
activate JNK apoptosis signalling instead of favouring in Wnt
signalling activation (Zhang et al, 2001). Indeed, the level of Akt
phosphorylation at Ser473 was reduced by the anti-Cripto Mab,
indicating the Mab acted as an inhibitor of Akt activation
(Figure 6B). Targeting Akt pathway has been successful in
attenuating chemotherapeutic resistance by small molecule in-
hibitor LY294002 (West et al, 2002). However, side effects and
acquired resistance have limited in clinical use of these small
molecular inhibitors. Moreover, many forms of cellular stress
including chemotherapeutic cytotoxics can also upregulate
PI3K/Akt signalling (West et al, 2002). Stress-induced activation
of PI3K/Akt pathway is regarded as a protective compensatory
mechanism for cells to escape chemotherapy-induced cell
death (Martelli et al, 2006). A rapid upregulation of PI3K/Akt
pathway has been observed in DAU-treated U937 human
leukaemia cells (Plo et al, 1999). In contrast to DAU, AraC
inhibited phosphorylation of Akt at Ser473, which was further
abolished by combined use of C4 with AraC (Figure 6B). Therefore,
the anti-Cripto Mab may be promising as a nonsmall molecule
inhibitor in clinical use to inhibit activation of Akt signal pathway
during chemotherapy.
Two principal pathways are involved in apoptosis: a pathway
that is directly activated by death receptors and a pathway that
involves mitochondria. Studies on the role of JNK in apoptotic
signalling revealed that JNK is required for the stress induced
apoptosis mediated by mitochondrial/caspase-9 pathway (Tour-
nier et al, 2000). Caspase-9, an important molecule to mediate
mitochondrial pathway, is a cell death protease, which is
phosphorylated and inactivated by Akt, and is cleaved by the
cytochrome c to initiate caspase cascade with requirement of JNK/
SAPK (Tournier et al, 2000). Our results showed that Cripto Mab
and AraC-induced cleavage of caspase 9 at Asp 330, which were
greatly amplified by the combined treatment of C4 and AraC,
indicating the activation of mitochondria/caspase-9 apoptosis
pathway is associated with a synergistic increase in the induction
of apoptosis (Figures 4C and 6B). The combination of C4 and AraC
had greater effects on JNK/SAPK activation and inhibition of Akt
phosphorylation that correlates a synergistic increase in the
induction of cleaved levels of casepase 9 (Figure 6A and B).
The mitochondria apoptosis pathway is primarily regulated by
Bcl-2 family proteins consisting of anti-apoptotic Bcl-2 and
Bcl-xL and proapoptotic members Bad and Bax (Petros et al,
2004). Bad forms a heterodimer with the anti-apoptotic proteins
Bcl-2 or Bcl-xL and thereby prevents them from exerting
their antiapoptotic function. Several signalling pathways influence
cell death through their effects on the phosphorylation of Bad
at various sites (Downward, 1999). Akt phosphorylates Bad at
Ser136, and promotes the association of Bad with 14-3-3 proteins
in the cytosol and inactivates Bad pro-apoptotic function
(Datta et al, 1997). Only the nonphosphorylated Bad heterodi-
merised with Bcl-xL at mitochondria membrane sites to promote
cell death. c-Jun N-terminal kinase/stress-activated protein kinase
phosphorylated Bcl-2 at Ser70 in vitro and in vivo. Phosphoryla-
tion of Bcl-2 at Ser70 inhibits the antiapoptotic function of Bcl-2
(Yamamoto et al, 1999). Anti-Cripto Mab, AraC dramatically
decrease phosphorylation of Bad at Ser136 and phosphorylation
of Bcl-2 at Ser70 in the CEM/A7R cells, and had little effect on
phosphorylation of Bad at Ser112, total level of Bad and Bcl-xL.
The combined use of Mab and AraC induced further decrease of
phosphorylation of Bad at Ser136 and Bcl-2 at Ser70 in the CEM/
A7R cells (Figure 6C). The data demonstrate that a mitochondrial
cell death pathway induced by anti-Cripto Mab is involved in the
inhibition of cell growth and overcoming drug resistance in the
MDR CEM/A7R.
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